Skip to Main Content

Paper Details

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Leukemia
42
2022
Author NameAffiliation
Jorge CortesGeorgia Cancer Center
Michael W DeiningerUniversity of Utah Health Care
  • 1 - 2

Datasets

Release 1.2